245 related articles for article (PubMed ID: 18323793)
1. Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial.
White CL; Twigger KR; Vidal L; De Bono JS; Coffey M; Heinemann L; Morgan R; Merrick A; Errington F; Vile RG; Melcher AA; Pandha HS; Harrington KJ
Gene Ther; 2008 Jun; 15(12):911-20. PubMed ID: 18323793
[TBL] [Abstract][Full Text] [Related]
2. A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer.
Vidal L; Pandha HS; Yap TA; White CL; Twigger K; Vile RG; Melcher A; Coffey M; Harrington KJ; DeBono JS
Clin Cancer Res; 2008 Nov; 14(21):7127-37. PubMed ID: 18981012
[TBL] [Abstract][Full Text] [Related]
3. A phase I trial of intratumoral administration of recombinant oncolytic adenovirus overexpressing HSP70 in advanced solid tumor patients.
Li JL; Liu HL; Zhang XR; Xu JP; Hu WK; Liang M; Chen SY; Hu F; Chu DT
Gene Ther; 2009 Mar; 16(3):376-82. PubMed ID: 19092859
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of cyclophosphamide as an immune modulator for optimizing oncolytic reovirus delivery to solid tumors.
Roulstone V; Khan K; Pandha HS; Rudman S; Coffey M; Gill GM; Melcher AA; Vile R; Harrington KJ; de Bono J; Spicer J
Clin Cancer Res; 2015 Mar; 21(6):1305-12. PubMed ID: 25424857
[TBL] [Abstract][Full Text] [Related]
5. Identification of CD8+CD25+Foxp3+ suppressive T cells in colorectal cancer tissue.
Chaput N; Louafi S; Bardier A; Charlotte F; Vaillant JC; Ménégaux F; Rosenzwajg M; Lemoine F; Klatzmann D; Taieb J
Gut; 2009 Apr; 58(4):520-9. PubMed ID: 19022917
[TBL] [Abstract][Full Text] [Related]
6. Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies.
Karapanagiotou EM; Roulstone V; Twigger K; Ball M; Tanay M; Nutting C; Newbold K; Gore ME; Larkin J; Syrigos KN; Coffey M; Thompson B; Mettinger K; Vile RG; Pandha HS; Hall GD; Melcher AA; Chester J; Harrington KJ
Clin Cancer Res; 2012 Apr; 18(7):2080-9. PubMed ID: 22316603
[TBL] [Abstract][Full Text] [Related]
7. Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer.
Robertson MJ; Cameron C; Atkins MB; Gordon MS; Lotze MT; Sherman ML; Ritz J
Clin Cancer Res; 1999 Jan; 5(1):9-16. PubMed ID: 9918197
[TBL] [Abstract][Full Text] [Related]
8. A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer.
Small EJ; Carducci MA; Burke JM; Rodriguez R; Fong L; van Ummersen L; Yu DC; Aimi J; Ando D; Working P; Kirn D; Wilding G
Mol Ther; 2006 Jul; 14(1):107-17. PubMed ID: 16690359
[TBL] [Abstract][Full Text] [Related]
9. Differential responses of cellular immunity in patients undergoing neoadjuvant therapy followed by surgery for carcinoma of the oesophagus.
Westerterp M; Boermeester MA; Omloo JM; Hulshof MC; Vervenne WL; Lutter R; Out TA; van Lanschot JJ
Cancer Immunol Immunother; 2008 Dec; 57(12):1837-47. PubMed ID: 18398607
[TBL] [Abstract][Full Text] [Related]
10. Clinical trials involving the oncolytic virus, reovirus: ready for prime time?
Black AJ; Morris DG
Expert Rev Clin Pharmacol; 2012 Sep; 5(5):517-20. PubMed ID: 23121273
[TBL] [Abstract][Full Text] [Related]
11. Possible biological indicators of the response to recombinant tumour necrosis factor alpha in patients with advanced neoplasms.
Braczkowski R; Zubelewicz B; Romanowski W; Lissoni P; Brivio F
J Exp Clin Cancer Res; 1998 Sep; 17(3):349-54. PubMed ID: 9894774
[TBL] [Abstract][Full Text] [Related]
12. Immune characterization of metastatic colorectal cancer patients post reovirus administration.
Parakrama R; Fogel E; Chandy C; Augustine T; Coffey M; Tesfa L; Goel S; Maitra R
BMC Cancer; 2020 Jun; 20(1):569. PubMed ID: 32552875
[TBL] [Abstract][Full Text] [Related]
13. Phase I evaluation of humanized OKT3: toxicity and immunomodulatory effects of hOKT3gamma4.
Richards J; Auger J; Peace D; Gale D; Michel J; Koons A; Haverty T; Zivin R; Jolliffe L; Bluestone JA
Cancer Res; 1999 May; 59(9):2096-101. PubMed ID: 10232594
[TBL] [Abstract][Full Text] [Related]
14. Unconventional cytokine profiles and development of T cell memory in long-term survivors after cancer vaccination.
Kyte JA; Trachsel S; Risberg B; thor Straten P; Lislerud K; Gaudernack G
Cancer Immunol Immunother; 2009 Oct; 58(10):1609-26. PubMed ID: 19221745
[TBL] [Abstract][Full Text] [Related]
15. Minimally invasive versus open Roux-en-Y gastric bypass: effect on immune effector cells.
Whitson BA; D'Cunha J; Hoang CD; Wu B; Ikramuddin S; Buchwald H; Panoskaltsis-Mortari A; Kratzke RA; Miller JS; Maddaus MA
Surg Obes Relat Dis; 2009; 5(2):181-93. PubMed ID: 18996756
[TBL] [Abstract][Full Text] [Related]
16. The use of immunohistochemistry to determine oncolytic reovirus distribution and replication in-human tumors.
Kapadia R; Coffey MC
Methods; 2010 Dec; 52(4):301-6. PubMed ID: 20801221
[TBL] [Abstract][Full Text] [Related]
17. Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers.
Harrington KJ; Karapanagiotou EM; Roulstone V; Twigger KR; White CL; Vidal L; Beirne D; Prestwich R; Newbold K; Ahmed M; Thway K; Nutting CM; Coffey M; Harris D; Vile RG; Pandha HS; Debono JS; Melcher AA
Clin Cancer Res; 2010 Jun; 16(11):3067-77. PubMed ID: 20484020
[TBL] [Abstract][Full Text] [Related]
18. Thoracoscopic versus thoracotomy approaches to lobectomy: differential impairment of cellular immunity.
Whitson BA; D'Cunha J; Andrade RS; Kelly RF; Groth SS; Wu B; Miller JS; Kratzke RA; Maddaus MA
Ann Thorac Surg; 2008 Dec; 86(6):1735-44. PubMed ID: 19021967
[TBL] [Abstract][Full Text] [Related]
19. Impairment of T helper and T regulatory cell responses at birth.
Schaub B; Liu J; Schleich I; Höppler S; Sattler C; von Mutius E
Allergy; 2008 Nov; 63(11):1438-47. PubMed ID: 18925880
[TBL] [Abstract][Full Text] [Related]
20. Reovirus - possible therapy of cancer.
Figova K; Hrabeta J; Eckschlager T
Neoplasma; 2006; 53(6):457-62. PubMed ID: 17167712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
